Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more
Neuren Pharmaceuticals Limited (NURPF) - Total Liabilities
Latest total liabilities as of June 2025: $7.98 Million USD
Based on the latest financial reports, Neuren Pharmaceuticals Limited (NURPF) has total liabilities worth $7.98 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neuren Pharmaceuticals Limited - Total Liabilities Trend (2004–2024)
This chart illustrates how Neuren Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neuren Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Neuren Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viad Corp
NYSE:VVI
|
USA | $1.00 Billion |
|
Tansun Technology Co Ltd
SHE:300872
|
China | CN¥730.71 Million |
|
Hongta Securities Co Ltd
SHG:601236
|
China | CN¥31.73 Billion |
|
Aditya Birla Real Estate Limited
NSE:ABREL
|
India | ₹133.87 Billion |
|
Shanghai Emperor of Cleaning Hi-Tech Co Ltd
SHG:603200
|
China | CN¥548.17 Million |
|
Event Hospitality & Entertainment Limited
F:AQHE
|
Germany | €1.64 Billion |
|
Jiangsu Yinhe Electronics Co Ltd
SHE:002519
|
China | CN¥1.04 Billion |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
China | CN¥2.36 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Neuren Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 40.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuren Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuren Pharmaceuticals Limited (2004–2024)
The table below shows the annual total liabilities of Neuren Pharmaceuticals Limited from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $45.80 Million | +7.11% |
| 2023-12-31 | $42.76 Million | +2448.45% |
| 2022-12-31 | $1.68 Million | +108.97% |
| 2021-12-31 | $803.00K | +6.64% |
| 2020-12-31 | $753.00K | +34.70% |
| 2019-12-31 | $559.00K | -71.67% |
| 2018-12-31 | $1.97 Million | +24.87% |
| 2017-12-31 | $1.58 Million | -22.05% |
| 2016-12-31 | $2.03 Million | -18.98% |
| 2015-12-31 | $2.50 Million | -17.37% |
| 2014-12-31 | $3.03 Million | +47.13% |
| 2013-12-31 | $2.06 Million | -3.89% |
| 2012-12-31 | $2.14 Million | +27.20% |
| 2011-12-31 | $1.68 Million | -22.90% |
| 2010-12-31 | $2.18 Million | -25.64% |
| 2009-12-31 | $2.94 Million | -1.19% |
| 2008-12-31 | $2.97 Million | -57.76% |
| 2007-12-31 | $7.04 Million | +108.31% |
| 2006-12-31 | $3.38 Million | +10.88% |
| 2005-12-31 | $3.05 Million | -27.41% |
| 2004-12-31 | $4.20 Million | -- |